The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Patients should have faster access to newly developed drugs and medicines and the Government is prepared to adopt new ...

The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

The global rise in obesity and type 2 diabetes is fueling an epidemic of MASLD and MASH, now recognized as the leading cause ...

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

Hyderabad (Telangana) [India], February 25 (ANI): Biological E Limited (BE) on Tuesday announced a strategic partnership with Bavarian Nordic A/S (OMX: BAVA) to expand access to Bavarian Nordic's ...

Healx has dosed the first patient in a Phase II trial assessing its lead pipeline candidate HLX-1502 in patients with neurofibromatosis type 1 (NF1), while the FDA approved SpringWorks Therapeutics’ ...

Nick Alves was 19 when a psychiatrist offered him the antidepressant Trintellix to treat his moderate anxiety and depression ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...